NanoMed’s technology is primarily targeting two very difficult clinical situations (pancreatic and metastatic colorectal cancer) where current treatments are ineffective. Pancreatic cancer often presents in an advanced state when patients are jaundiced with liver dysfunction. Current management of these cases involves the use of neoadjuvant therapy usually involving gemcitabine, which is poorly tolerated.

What is needed is a chemotherapy delivery method which provides an effective dose to the cancer but not to normal tissue.  NanoMed’s drug delivery technology has shown preferential uptake with high drug payload in tumours in mouse studies at much lower doses compared to conventional drugs. 

Lower doses and reduced side effects reduce complications such as neutropenia that need to be managed and are expensive to treat. Combination chemotherapies involving more than one drug, which NanoMed technology is capable of providing, show improved outcomes for more advanced cancer patients with less side effects. 

The many benefits of NanoMed’s prodrug nanomedicines over similar technologies include:

• Biocompatibility
• Delivery into cancer cells by controlled nanoparticle size and active peptide targeting
• Protection of prodrug against biodegradation before it is delivered to the site of action
• Ready formation of stable nanomedicines by modular and bottom-up self-assembly of components in aqueous systems
• Several chemotoxic drugs and diagnostic agents can be loaded together without problematic cross reaction
• Low-cost and large-scale production with no unexpected challenges.